Introduction to Stability Studies

The development of stability data is a critical component in the tablet formulation and design process. Stability studies provide essential information about how the quality of a drug product varies with time under the influence of environmental factors such as temperature, humidity, and light.

Key Principle:

The final tablet formulation should be placed on stability as soon as possible after its development. Additionally, formulations that "cover" the proposed excipient ranges may also be placed on stability to evaluate the impact of excipient variations.

Comprehensive Stability Evaluation:

Stability data should be generated with the tablet in all expected packaging configurations (i.e., blisters, plastic and glass bottles, etc.). This ensures that the stability profile is understood across all potential market presentations.

Design Basis for Stability Studies

The design of formal stability studies for the drug product should be based on:

  • Knowledge of the behavior and properties of the drug substance
  • Results from stability studies on the drug substance
  • Experience gained from formulation development studies

Photostability Testing

Photostability testing assesses the impact of light exposure on drug product quality. This is particularly important for light-sensitive active pharmaceutical ingredients (APIs) and formulations.

Regulatory Requirement:

Photostability testing should be conducted on at least one primary batch of the drug product if appropriate for the formulation.

Photostability Testing Protocol:

ICH Q1B Guidelines

According to ICH guidance, drugs must be exposed to at least:

  • 1.2 million lux-hours of visible light
  • 200 WHr/m² of UVA (near UV) light

Light Source Options:

ICH Q1B guidelines allow for two light source options for photostability testing:

Option I - Single Light Source

Testing is performed with a wide-range light source, encompassing both near UV (UVA) and visible light spectra. The light source is typically either:

  • Fluorescent D65
  • Xenon lamp
  • Metal halide (HID) lamp

Option II - Dual Light Sources

Uses two different lamp types:

  • Fluorescent cool white lamps for VIS exposure
  • Near UV fluorescent lamps (320 nm to 400 nm) for UVA exposure

Special Consideration:

For some products where it has been demonstrated that the immediate pack is completely impenetrable to light (such as aluminium tubes or cans), testing should normally only be conducted on directly exposed product.

Selection of Batches for Stability Studies

Minimum Batch Requirement:

Data from stability studies should be provided on at least three primary batches of the drug product.

Characteristics of Primary Batches:

  • The primary batches should be of the same formulation as proposed for marketing
  • They should be packaged in the same container closure system as proposed for marketing
  • The manufacturing process should simulate that to be applied to production batches
  • Should provide product of the same quality and meeting the same specifications as that intended for marketing

Batch Scale Requirements:

  • Two of the three batches should be at least pilot scale batches
  • The third batch can be smaller if justified
  • Where possible, batches of the drug product should be manufactured using different batches of the drug substance

Testing Scope:

  • Stability studies should be performed on each individual strength and container size of the drug product unless bracketing or matrixing is applied
  • Stability testing should be conducted on the dosage form packaged in the container closure system proposed for marketing (including, as appropriate, any secondary packaging and container label)

Storage Conditions for Stability Studies

The storage conditions and the lengths of studies chosen should be sufficient to cover storage, shipment, and subsequent use of the drug product.

Purpose of Different Storage Conditions:

  • Long-term conditions: Simulate actual storage conditions over the product's shelf life
  • Intermediate conditions: Provide additional data when significant change occurs at accelerated conditions
  • Accelerated conditions: Increase the rate of chemical degradation to predict stability issues in shorter timeframes

Climate Zones and Storage Conditions:

Zone I & II

Temperate regions

Long-term: 25°C ± 2°C / 60% RH ± 5% RH

Zone IVA

Hot and humid regions

Long-term: 30°C ± 2°C / 65% RH ± 5% RH

Zone IVB

Very hot and humid regions

Long-term: 30°C ± 2°C / 75% RH ± 5% RH

Study Type Storage Conditions Testing Frequency (Months)
Long-term 25°C ± 2°C / 60% RH ± 5% RH (Zone I & II)
30°C ± 2°C / 65% RH ± 5% RH (Zone IVA)
30°C ± 2°C / 75% RH ± 5% RH (Zone IVB)		 0, 3, 6, 9, 12, 18, 24, 36
Intermediate 30°C ± 2°C / 65% RH ± 5% RH 0, 3, 6, 9, 12
Accelerated 40°C ± 2°C / 75% RH ± 5% RH 0, 3, 6

Important Notes:

  • It is up to the applicant to decide whether long-term stability studies are performed at 25°C/60% RH or 30°C/65% RH
  • If 30°C ± 2°C/65% RH ± 5% RH is selected as the long-term condition, there is no intermediate condition required
  • The selection of storage conditions should be justified based on the intended market and climatic conditions

Testing Frequency and Protocol

Long-term Studies:

Testing should be performed at minimum intervals of 3 months during the first year, 6 months during the second year, and annually thereafter. For products with a proposed shelf life of at least 12 months, the testing frequency should be:

  • 0, 3, 6, 9, 12, 18, 24, and 36 months
  • Beyond 36 months, testing should be conducted annually until the proposed shelf life is covered

Accelerated Studies:

Testing under accelerated conditions is typically conducted for 6 months:

  • 0, 3, and 6 months
  • If significant change occurs within 3 months, additional testing at the intermediate condition may be necessary

Intermediate Studies:

When significant change occurs at accelerated conditions, testing at intermediate conditions becomes necessary:

  • 0, 3, 6, 9, and 12 months
  • Provides additional data to establish shelf life when accelerated conditions are too harsh

Photostability Testing Protocol

Development Phase vs. Confirmatory Studies:

Development Phase

Normally, only one batch of product is tested during the development phase to understand the photostability characteristics of the formulation.

Confirmatory Studies

The photostability characteristics should be confirmed on a single batch selected as described in the Parent Guideline. If the results of the confirmatory study are equivocal, testing of up to two additional batches should be conducted.

Key Points in Photostability Testing:

  • The product should be exposed to light providing an overall illumination of not less than 1.2 million lux hours
  • Near ultraviolet energy of not less than 200 watt hours per square meter should be integrated
  • Samples should be positioned to provide maximum area of exposure to the light source
  • Both drug product and drug substance may need testing depending on the packaging

Evaluation Criteria:

After exposure, the samples should be evaluated for:

  • Changes in appearance (color, clarity, precipitation)
  • Assay of active substance
  • Degradation products
  • Physical properties (dissolution, hardness, friability for tablets)

Implementation Strategy

  1. Early Stability Testing: Initiate stability studies as soon as the final formulation is developed to gather data throughout the development process.
  2. Batch Selection: Ensure at least three primary batches are selected, with two at pilot scale, representing the proposed commercial manufacturing process.
  3. Comprehensive Packaging Testing: Test stability in all proposed packaging configurations to understand package-specific stability profiles.
  4. Climate Zone Consideration: Select appropriate storage conditions based on intended markets and their climate zone classifications.
  5. Photostability Assessment: Conduct appropriate photostability testing based on drug substance sensitivity and packaging characteristics.
  6. Data Documentation: Maintain comprehensive records of all stability testing, including deviations, out-of-specification results, and investigations.
  7. Regulatory Submission: Prepare stability data according to ICH guidelines for regulatory submission, including proposed shelf life and storage conditions.

Final Considerations:

Stability studies are not just a regulatory requirement but a critical component of ensuring patient safety and product efficacy throughout the shelf life. Properly designed and executed stability studies provide the scientific basis for establishing expiration dates, storage conditions, and packaging requirements for tablet formulations.